PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
121.05%
EBIT growth of 121.05% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
-6.92%
Negative operating income growth while Healthcare median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
121.05%
Net income growth of 121.05% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
121.15%
EPS growth of 121.15% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
115.11%
Diluted EPS growth of 115.11% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
2.25%
Share change of 2.25% while Healthcare median is zero. Walter Schloss would see if the modest difference matters long-term.
42.15%
Diluted share change of 42.15% while Healthcare median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
-3.22%
Negative OCF growth while Healthcare median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-8.23%
Negative FCF growth while Healthcare median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-39049.73%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-717224.10%
Negative 5Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-12351.82%
Negative 3Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
45138.86%
Net income/share CAGR exceeding 1.5x Healthcare median of 14.34% over a decade. Joel Greenblatt might see a standout compounder of earnings.
41496.01%
5Y net income/share CAGR > 1.5x Healthcare median of 7.30%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
7331.25%
3Y net income/share CAGR of 7331.25% while Healthcare median is zero. Walter Schloss might see a small advantage that can be scaled further.
8529.17%
Equity/share CAGR of 8529.17% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
2357.47%
5Y equity/share CAGR of 2357.47% while Healthcare median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
2495.43%
3Y equity/share CAGR of 2495.43% while Healthcare median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
135.47%
Asset growth of 135.47% while Healthcare median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
131.44%
BV/share growth of 131.44% while Healthcare is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-41.82%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
-18.65%
R&D dropping while Healthcare median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
44.07%
SG&A growth far above Healthcare median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.